Why is Eli Lilly spending $3.8 billion on vaccine developers?

Eli Lilly is acquiring Curevo Vaccine, LimmaTech Biologics, and Vaccine Company for up to $3.8 billion to expand into disease prevention. The deals give Lilly a late-stage shingles vaccine challenger, bacterial vaccine programs, and flavivirus research, signaling a strategic shift from therapeutics to large-scale vaccination and public health prevention.